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Abstract
Background. Symptom management in glioma patients remains challenging, as patients suffer from various con-
currently occurring symptoms. This study aimed to identify symptom clusters and examine the association be-
tween these symptom clusters and patients’ functioning.
Methods. Data of the CODAGLIO project was used, including individual patient data from previously published 
international randomized controlled trials (RCTs) in glioma patients. Symptom prevalence and level of functioning 
were assessed with European Organisation for Research and Treatment of Cancer (EORTC) quality of life QLQ-
C30 and QLQ-BN20 self-report questionnaires. Associations between symptoms were examined with Spearman 
correlation coefficients and partial correlation networks. Hierarchical cluster analyses were performed to identify 
symptom clusters. Multivariable regression analyses were performed to determine independent associations be-
tween the symptom clusters and functioning, adjusted for possible confounders.
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Results. Included in the analysis were 4307 newly diagnosed glioma patients from 11 RCTs who completed 
the EORTC questionnaires before randomization. Many patients (44%) suffered from 5–10 symptoms simul-
taneously. Four symptom clusters were identified: a motor cluster, a fatigue cluster, a pain cluster, and a 
gastrointestinal/seizures/bladder control cluster. Having symptoms in the motor cluster was associated with 
decreased (≥10 points difference) physical, role, and social functioning (betas ranged from −11.3 to −15.9, 
all P < 0.001), independent of other factors. Similarly, having symptoms in the fatigue cluster was found to 
negatively influence role functioning (beta of −12.3, P < 0.001), independent of other factors.
Conclusions. Two symptom clusters, the fatigue and motor cluster, were frequently affected in glioma pa-
tients and were found to independently have a negative association with certain aspects of patients’ func-
tioning as measured with a self-report questionnaire.
Key Points
1. Four symptom clusters were identified in newly diagnosed glioma patients.
2.  The motor and fatigue cluster were associated with decreased functioning.
3.  Comprehensive symptom assessment is important to address symptoms in a 
timely manner.
Patients with a glioma, the most prevalent malignant primary 
brain tumor,1 suffer from a variety of symptoms during the 
course of disease, including fatigue, cognitive problems, be-
havioral problems, and motor dysfunction.2 Many patients 
experience more than one symptom simultaneously,3 and 
typically more symptoms are experienced than are reported 
to or detected by clinicians.4,5 Depending on the definition, 2 
or more symptoms that are related to each other and occur 
together are referred to as a symptom cluster, and associ-
ations between symptoms within a symptom cluster are 
stronger than associations among different symptom clus-
ters and/or separate symptoms.6,7 Identification of these 
symptom clusters may aid symptom management, because 
the co-occurrence of symptoms may have a larger impact on 
patients’ functioning and overall health-related quality of life 
(HRQoL) than each symptom alone.8 If management is aimed 
at improvement of patients’ functioning, targeting these spe-
cific symptom clusters may provide an opportunity.
In other cancer populations, several symptom clusters 
have been identified9,10 which were found to be associ-
ated with patients’ functioning. In glioma patients, how-
ever, symptom clusters have not been studied sufficiently. 
The few studies that were conducted have limitations, 
including limited sample sizes or the lack of inclusion of 
glioma-specific symptoms.9,11,12 Patients with a glioma may 
suffer from generic cancer symptoms such as fatigue and 
mood disorders, but also from disease-specific symptoms 
such as seizures, headaches, motor deficits, or cognitive 
deficits.13,14 Both these generic and disease-specific symp-
toms may be associated with a patients’ well-being and 
functioning, including physical, role, emotional, cognitive, 
and social functioning.
The aim of this study was to identify symptom clusters 
in a large sample of newly diagnosed glioma patients, 
and to investigate the associations between the identified 
symptom clusters and patients’ functioning and global 
health status/quality of life.
Methods
Study Population
Patients included in this study participated in previ-
ously published phase II and III randomized controlled 
trials (RCTs) including adult patients with both recur-
rent and newly diagnosed glioma (Supplementary Table 
1). Over 6000 patients are included in the CODAGLIO (ie, 
COmbining clinical trial DAtasets in GLIOma) project.15 
For the purpose of the current analysis, focusing on 
identifying symptoms clusters at the time of diagnosis, 
only RCTs involving newly diagnosed glioma patients 
and using the European Organisation for Research and 
Importance of the Study
This study identified 4 symptom clusters in a large 
group of newly diagnosed glioma patients, assessed 
with the EORTC self-report health-related quality of 
life questionnaires. The motor cluster was found to 
negatively influence patients’ physical, role, and so-
cial functioning to a significant and clinically relevant 
extent, independently of other sociodemographic and 
clinical variables. Similarly, the fatigue cluster nega-
tively impacted role functioning. Therefore, relieving 
symptoms in the fatigue and motor clusters may guide 
symptom management in newly diagnosed glioma 
patients.
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Treatment of Cancer (EORTC) Quality of Life Questionnaire 
C30 (QLQ-C30) and QLQ–Brain Neoplasm (BN)20 module 
were included. All RCTs were approved by the ethical com-
mittees of all participating centers and all patients gave 
their informed consent to participate in the respective 
RCT. Moreover, all principal investigators of these RCTs 
gave permission for use of the collected data within the 
CODAGLIO project.
Measurements
Generic cancer-specific and brain tumor–specific symp-
toms, as well as levels of functioning, were measured 
with the EORTC QLQ-C30 and the QLQ-BN20 ques-
tionnaire. The EORTC QLQ-C30 version 3.016 and the 
brain-cancer specific QLQ-BN2017 were administered at 
baseline, ie, before the start of the allocated treatment 
(after surgery and irrespective of supportive treatment), 
and at prespecified timepoints during follow-up. The 
EORTC QLQ-C30 is the core EORTC questionnaire that in-
cludes 30 items, comprising 5 functioning scales (phys-
ical, role, emotional, cognitive, and social functioning), 
3 symptom scales (fatigue, pain, and nausea/vomiting), 
a global health status/quality of life scale, and 6 single 
items (dyspnea, appetite loss, insomnia, constipation, di-
arrhea, and financial difficulties). The QLQ-BN20 is specif-
ically designed for brain tumor patients and consists of 
20 items in 4 symptom scales (future uncertainty, visual 
disorder, motor dysfunction, and communication def-
icit) and 7 single items (headaches, seizures, drowsiness, 
hair loss, itchy skin, weakness of legs, and bladder con-
trol). Responses for all items are on a 4-point Likert scale 
(ie, not at all, a little, quite a bit, and very much), except 
for the global health status/quality of life scale, which is 
scored on a 7-point Likert scale ranging from very poor to 
excellent. For both questionnaires, raw scores were line-
arly transformed to a scale from 0 to 100 according to the 
standard EORTC procedures.18 For the functioning scales 
and the global health status/QoL scale, a higher score 
indicates a better HRQoL. For the symptom scales and 
items, higher scores indicate more symptoms and worse 
functioning, respectively.
Other sociodemographic and clinical variables col-
lected included age, sex, type of tumor (World Health 
Organization [WHO] grade II or III astrocytoma, oligo-
dendroglioma, and oligoastrocytoma, or grade IV glioblas-
toma), WHO performance status (PS) (0 vs 1 vs 2), and type 
of surgery (resection vs biopsy).
Statistical Analysis
Descriptive methods were used to summarize baseline 
sociodemographic, clinical, and HRQoL data, including the 
prevalence and severity of symptoms. For this study, only 
fully completed baseline HRQoL forms were considered. 
To evaluate differences between patients with and without 
a completed HRQoL baseline form (ie, possible selection 
bias), several clinical characteristics were compared using 
the chi-square test for categorical data and an independent 
Student’s t-test for continuous variables. Mean scores 
on the functioning scales of the included patients were 
compared with a healthy normgroup to have an indication 
of the level of functioning of the included patients.19
Clustering of the symptoms was carried out in 3 steps, 
and we chose to define a symptom cluster as having a 
minimum of 2 symptoms. First, to explore symptom clus-
tering, Spearman correlational analyses were carried out 
on all symptom scales and single items of the EORTC QLQ-
C30 and QLQ-BN20, except financial difficulties and future 
uncertainty, which we did not classify as symptoms (ie, 
defined as “a physical or mental feature which is regarded 
as indicating a condition of disease”). The magnitudes of 
the correlations were interpreted as follows: between 0 
and ±0.3 as “little if any”; between ±0.3 and ±0.5 as “low”; 
between ±0.5 and ±0.7 as “moderate”; and above ±0.7 
as “high.” 20 Next, the associations among the symptoms 
were presented in an unregularized partial correlation net-
work based on Spearman correlations, which was used to 
examine whether the associations between the symptoms 
were still present when adjusting for the other symptoms. 
The network model was estimated using the Gaussian 
graphical model, which estimates a network of partial 
correlation coefficients.21,22 Network models provide an 
alternative method to visualize associations and consist 
of nodes (circles = the symptoms) and edges (lines = the 
relation between the symptoms). Each link in the net-
work represents a partial correlation coefficient between 2 
symptoms after controlling for the other symptoms. We in-
cluded at least 2 symptoms in the symptom clusters.
Thereafter, hierarchical cluster analysis (HCA) was per-
formed as a last step to assess how the symptom scales/
items cluster.23 HCA is an exploratory technique that iden-
tifies groups of symptoms based on similarity between 
them: symptoms within the same cluster resemble each 
other but differ from those in another symptom cluster.24 
The symptoms were included as continuous variables in 
the HCA and the similarity between the different clusters 
was assessed with the average-linkage-between-groups 
method, using the Euclidean distance. A dendrogram for 
the symptom clusters was plotted to illustrate the arrange-
ment of the variables produced by clustering. A stronger 
similarity between the symptoms is reflected by a smaller 
distance between the branches. In order to determine the 
optimal number of clusters, a range of clusters from one 
(all symptoms clustered together) to 18 (all symptoms as 
separate single symptoms) was produced in the cluster 
membership analysis. The optimal number of clusters was 
based on the results of all 3 steps: the correlation analysis, 
the partial Spearman matrix, and the HCA. Subanalyses in 
predefined subgroups based on sex, age (<55 vs ≥55 y), 
WHO performance status (PS = 0/1 vs PS = 2), resection (bi-
opsy vs resected), and type of tumor (glioblastoma vs non-
glioblastoma) were performed to investigate whether the 
symptom clusters were invariant across subpopulations. 
Also, a subanalysis for tumor location was carried for pa-
tients with such information available.
After the identification of the clusters, patients were 
classified as having “symptoms” or “no symptoms” for 
both the symptom clusters and the single symptoms. 
Patients were classified as having symptoms when they re-
ported mild to severe symptoms on at least one item in a 
symptom cluster, or on the single symptoms. Thereafter, 
univariable linear regression analyses were performed to 
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determine the association between each symptom cluster 
and the 5 functioning scales (physical, cognitive, emo-
tional, role, and social functioning) and the global health 
status/QoL scale. Subsequently, 6 multivariable linear re-
gression analyses were performed for each functioning 
scale and the global health status/QoL scale, including the 
symptom cluster, single symptoms as well as relevant clin-
ical/sociodemographic variables (sex, age, WHO PS, type of 
tumor. and type of surgery), to determine the independent 
association between the symptom clusters and the func-
tioning scales and the global health status/QoL scale. All vari-
ables were included simultaneously, allowing adjustment for 
confounders for the associations between the symptom clus-
ters and functioning. In each multivariable regression model, 
a two-tailed P-value < 0.05 was considered statistically sig-
nificant. In terms of clinical relevance, beta coefficients ≥10 
were considered clinically relevant and beta coefficients ≥20 
were considered a large effect, corresponding with, respec-
tively, a 10 and 20 point change in HRQoL scores.25 Analyses 
were performed using IBM SPSS v23.026 and R27 with the 
qgraph package.22
Results
Patient Population
A total of 11 RCTs (Supplementary Table 1)28–38 were ana-
lyzed, comprising 5287 patients with newly diagnosed 
glioma, of whom 4307 patients (81%) completed a full 
HRQoL baseline form. When comparing patients who 
completed an HRQoL form with patients who did not, a se-
lection bias toward a healthier population was observed. 
Patients with an HRQoL form were younger (mean of 54 
vs 57 y, P  < 0.001), had a better WHO PS (percentage of 
patients with score 0–1 was 88% vs 81%, P = 0.001), more 
often had a resection rather than biopsy (82% vs 79%, 
P  =  0.025), and were less often diagnosed with glioblas-
toma (69% vs 73%, P = 0.007).
Level of Functioning and Symptom Prevalence 
and Severity
As a group, the included patients scored lower on all func-
tioning scales and the global health status/QoL scale compared 
with the general European population19 (≥10 points difference 
between the groups), representing an impairment in func-
tioning. On the individual patient level, impaired functioning 
was observed ranging from 38% of patients for physical func-
tioning to 69% of patients for cognitive functioning (Table 2).
On the individual patient level, 4183 of 4307 included 
patients (97%) who self-reported at least one symptom. 
Most patients tallied between 1 and 4 (40%) or between 
5 and 10 concurrent symptoms (44%), while 562 patients 
(13%) reported more than 10 concurrent symptoms (Table 
1). Among the 18 reported symptoms, fatigue was the 
most prevalent, experienced by 86% of patients, followed 
by drowsiness (60%) and motor dysfunction (55%) (Table 
2). In terms of severity of the symptoms, the majority of 
symptoms were experienced as mild, and less often as 
moderate or severe (Fig. 1).
  
Table 1  Baseline sociodemographic and clinical characteristics of all patients participating in the RCTs and separately for those who have a valid 
baseline HRQoL form
All Patients (n 
= 5287), n (%)
Patients Who Completed an 
HRQOL Form (n = 4307), n (%)
Patients Who Did Not Complete an  
HRQOL Baseline Form (n = 980), n (%)
P-value
Male 3191 (60) 2659 (62) 532 (54) <0.001
Female 2096 (40) 1648 (38) 448 (46)
Age (mean, SD) 54 (14) 54 (14) 57 (13) <0.001
Gr II/III, A/O/OA 1594 (30) 1331 (31) 263 (27) 0.007
Gr IV glioblastoma 3693 (70) 2976 (69) 717 (73)
WHO PS 0–1 4597 (87) 3805 (88) 792 (81) 0.001
WHO PS 2 659 (13) 487 (11) 172 (18)
Missing 31 (1) 15 (0) 16 (2)
Biopsy 985 (19) 780 (18) 205 (21) 0.025
Resection 4287 (81) 3514 (82) 773 (79)
Missing 15 (0) 13 (0) 2 (0)
0 symptoms - 124 (3) - -
1–4 concurrent 
symptoms
- 1725 (40) -
5–10 concurrent 
symptoms
- 1896 (44) -
>10 concurrent 
symptoms
- 562 (13) -
Gr, grade of the tumor; A, astrocytoma; O, oligondendroglioma; OA, oligoastrocytoma; SD, standard deviation.
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Symptom Clusters
The strength of the correlations between symptoms was 
low to moderate, ranging between 0.01 and 0.59, with the 
strongest correlations found for fatigue with drowsiness (.59) 
and motor dysfunction (.52), for pain and headache (.57), 
and for motor dysfunction with weakness of the legs (.52) 
(Supplementary Table 2). A graphical representation of the 
Spearman correlations between symptoms is presented in 
Fig. 2, based on the partial correlation matrix (Supplementary 
Table 3). Fatigue and motor dysfunction were the symptoms 
that showed the largest centrality in terms of closeness, 
betweenness, and strength (ie, measures indicating the im-
portance of the symptoms in the network, of the correlation 
with the other symptoms) (Supplementary Fig. 1).
Thereafter, HCA was performed to identify clusters based 
on the similarities between them, illustrated by the dendro-
gram (Fig. 3). Based on the correlation analyses, the partial 
correlation matrix, and the cluster membership analysis/
dendrogram, the clustering step consisting of 4 symptom 
clusters and 8 single symptoms was found most suitable 
based on both clinical considerations and the Spearman 
correlation matrix. The 4 symptom clusters were as follows: 
“pain cluster” (consisting of pain and headache), “motor 
cluster” (consisting of motor dysfunction and weakness 
of the legs), “fatigue cluster” (consisting of fatigue and 
drowsiness), and “gastrointestinal/seizures/bladder con-
trol cluster” (consisting of nausea and vomiting, diarrhea, 
seizures, and bladder control). The pain cluster, the motor 
cluster, and the fatigue cluster were consistently found 
across the subgroups—age, sex, WHO PS, tumor type, and 
surgery—while the gastrointestinal/seizures/bladder con-
trol cluster was not observed in patients with a low PS and 
non-glioblastoma patients (data not shown). Data on tumor 
location were available for 2283 of 4307 of patients (53%). 
The motor cluster and fatigue cluster were consistently 
found in patients with different tumor locations, whereas 
the pain cluster and the GI/seizures/bladder control cluster 
were not found across all tumor locations (data not shown).
Prevalence of the Symptom Clusters
Most patients (88%) experienced symptoms in the fatigue 
cluster, followed by the motor cluster (59%), the pain cluster 
(56%), and the GI/seizures/bladder control cluster (43%). 
The majority of patients experienced symptoms in several 
symptom clusters: 79% of the patients experienced symp-
toms in at least 2 clusters, 51% in at least 3 clusters, and 22% 
in all 4 clusters. The symptom clusters that occurred most 
frequently together were the fatigue and the motor cluster, 
which was experienced by 56% of the patients, and the fa-
tigue and pain cluster, experienced by 53% of the patients.
Association Between Symptom Clusters and 
Functioning and Global Health Status/Quality 
of Life
Results of the univariable regression analyses showed 
that the 4 symptom clusters negatively influenced all func-
tioning scales and the global health status/QoL scale, ex-
cept for the association between the pain cluster and 
physical functioning (betas ranged from −9.25 to −30.94, 
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Fig. 1 Severity of symptoms for the selected symptoms scales/items measured with the EORTC QLQ-C30 and QLQ-BN20 questionnaires. A darker 
color indicates more severe symptoms. The single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, headache, seizures, drowsiness, 
hair loss, itchy skin, weakness of the legs, and bladder control) were rated as: no, mild, moderate, and severe. For the symptom scales (fatigue, 
visual disorder, motor dysfunction, communication deficit, nausea and vomiting, and pain), the symptoms consisted of multiple items. The Fig. rep-
resents the severity on a 0–100 scale, where 0 (white) indicates no symptoms and 100 (black) indicates severe symptoms.
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all P < 0.001). Results of the multivariable regression ana-
lyses indicated that only the motor cluster and the fatigue 
cluster negatively influenced functioning in the presence 
of other factors (Table 3). The motor cluster had a clinically 
relevant negative impact on patients’ physical, role, and 
social functioning (betas ranged from −11.3 to −15.9, all 
P < 0.001), whereas the fatigue cluster had a clinically rele-
vant negative impact on the patient’s role functioning (beta 
−12.3, P  <  0.001). With respect to the single symptoms, 
visual disorder and communication deficit negatively in-
fluenced cognitive functioning in the presence of other fac-
tors (Table 3).
In addition, results of subanalyses showed that the 
impact of functioning was larger, and entailed more 
functioning scales in patients with symptoms in ≥3 
symptom clusters compared with patients with symp-
toms in only 1 or 2 clusters (data not shown). For 
example, when selecting only those patients with symp-
toms in 1 symptom cluster (13% of the patients), there 
was no clinical impact on patients’ functioning scales. 
When selecting patients who experienced symptoms in 
≥3 clusters (51% of the patients), the motor cluster had 
a clinically relevant negative impact on the same func-
tioning scales, but with a larger impact (betas ranged 
from −13.4 to −16.6), and the fatigue cluster had a clini-
cally relevant negative impact on global health, physical 
functioning, and social functioning, in addition to role 
functioning. Also, the impact was larger (betas ranged 
from −13.3 for the global health status to −27.8 for role 
functioning). Consequently, patients who experience 
symptoms in more symptom clusters are likely to expe-
rience a larger impact on functioning.
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Fig. 2 Spearman correlation matrix of selected symptoms measured 
with the EORTC QLQ-C30 and QLQ-BN20 questionnaires. Thicker and 
darker lines represent stronger partial correlations. Continued lines 
represent positive partial correlations, dotted lines represent neg-
ative partial correlations. The position of the variables represent the 
closeness, node strength, and betweenness of the variables. Central 
variables with more connections and thicker lines are most strongly 
correlated with other variables. AP, appetite loss; BC, bladder control; 
CD, communication deficit; CO, constipation; DI, diarrhea; DY, dyspnea; 
DR; drowsiness; FA, fatigue; HA, headache; HL, hair loss; SL, insomnia; 
IS, itchy skin; MD, motor dysfunction; NV, nausea and vomiting; PA, 
pain; SE, seizures; VD, visual disorder; WL, weakness of the legs.
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Fig. 3 Dendrogram illustrating the results of the hierarchical cluster analysis (HCA). The distance at which the branches join indicates the simi-
larity between the symptoms (shorter branches represent greater similarity). Symptoms with greater similarity were clustered first, presented on 
the left side of the figure. This cluster analysis shows that nausea and vomiting were clustered as a first step, followed by seizures (step 2). Next, 
pain and headache (step 3) and motor dysfunction and weakness of the legs were clustered (step 4), and so on. The optimal number of clusters was 
determined at step 6, resulting in the 4 clusters indicated in this Fig. (indicated in gray).
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Discussion
The results of this study show that glioma patients experi-
ence multiple symptoms simultaneously shortly after sur-
gery, but before initiation of further antitumor treatment. 
This suggests the need for comprehensive symptom assess-
ment at baseline, in order to address symptoms in a timely 
manner. Consistent with the literature, overall quality of life 
and functioning was impaired at randomization (ie, before 
the start of the allocated treatment, reflecting the impact of 
the disease and possible surgical and supportive treatment 
side effects such as fatigue, insomnia, and nausea/vomiting). 
The most frequently reported symptoms, occurring in more 
than 40% of the patients, were fatigue, drowsiness, motor 
dysfunction, communication deficits, insomnia, visual dis-
orders, and headache/pain, corresponding with the core 
symptoms in glioma patients.8,39–42 Results of the correlation 
analyses (revealing low to moderate correlations), partial 
correlation matrix, and HCA together identified 4 symptom 
clusters: a pain cluster, a motor cluster, a fatigue cluster, and 
a GI/seizures/bladder cluster.
The fatigue cluster, comprising both fatigue and drow-
siness, was most often prevalent (88%). This result indi-
cates fatigue already is an important symptom in early 
stages of disease, as patients included in this study were 
newly diagnosed, assessed after surgery but before further 
antitumor treatment. In a previous study in primary brain 
tumor patients, fatigue clustered with pain, insomnia, 
motor problems, and depression.8 Although these results 
were not replicated in the current study, fatigue was more 
strongly associated with pain, insomnia, and motor prob-
lems compared with the other symptoms in terms of cor-
relations and position in the network matrix (Fig. 2). Mood 
disorders/complaints were not assessed in the current 
study as a single symptom. Nevertheless, the emotional 
functioning scale, which entails questions on mood, was 
not found to be independently associated with the fatigue 
cluster in our study.
The second most prevalent cluster was the motor cluster, 
experienced by 59% of patients. Motor dysfunction and 
muscle weakness can both be caused by the presence of a 
tumor in the motor brain region, or even when the tumor 
is located outside the motor cortex, due to diminished 
  
Table 2  Number of patients with impaired functioning and with symptoms
Functioning Scales Mean (SD) Patients with Impaired Functioning,a n (%)
Global health status 63.9 (22.6) 1828 (42)
Physical functioning 81.5 (22.1) 1648 (38)
Role functioning 65.2 (33.3) 2351 (55)
Emotional functioning 71.7 (23.8) 1824 (42)
Cognitive functioning 72.5 (27.3) 2961 (69)
Social functioning 69.3 (30.3) 2865 (67)
Symptoms mean (SD) Patients with symptoms,b n (%)
Fatigue (scale) 34.9 (25.3) 3706 (86)
Nausea and vomiting 
(scale)
4.6 (12.1) 759 (18)
Pain (scale) 14.7 (21.7) 1882 (44)
Dyspnea (item) 10.9 (21.3) 1063 (25)
Insomnia (item) 24.9 (29.9) 2135 (50)
Appetite loss (item) 10.8 (22.1) 1008 (23)
Constipation (item) 12.7 (24.2) 1135 (26)
Diarrhea (item) 5.6 (15.5) 588 (14)
Visual disorder (scale) 13.2 (20.3) 1924 (45)
Motor dysfunction (scale) 17.4 (22.8) 2363 (55)
Communication deficit 
(scale)
19.1 (25.6) 2304 (54)
Headache (item) 19.9 (26.3) 1894 (44)
Seizures (item) 6.1 (18.6) 519 (12)
Drowsiness (item) 27.5 (27.4) 2593 (60)
Hair loss (item) 9.8 (22.8) 833 (19)
Itchy skin (item) 9.8 (20.8) 949 (22)
Weakness of legs (item) 14.8 (26.0) 1288 (30)
Bladder control (item) 8.1 (20.3) 726 (17)
aPatients who reported a ≥10 points lower score compared with the normgroup18; bpatients who reported any symptoms (mild to severe)
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functional connectivity.43 Also, it can be a side effect of cor-
ticosteroids. Indeed, patients who used corticosteroids re-
ported more problems in the motor cluster (67% vs 52%). 
We found that pain and headache clustered together, and 
one reason may be that pain has many dimensions and pa-
tients may have interpreted the item “Have you had pain” 
  
Table 3  Multivariable linear regression analysis showing the association between the four symptom clusters and the functional scales and the 
global health status/quality of life scale, adjusted for important confounding variables
Cluster HRQoL Functioning Scales beta, P-value
Global Health 
Status/QoL 
Scale
Physical 
Functioning
Role Func-
tioning
Emotional 
Functioning
Cognitive 
Functioning
Social 
Functioning
Symptom clusters a
Pain −5.7 −2.9 −4.9 −5.4 −3.5 −3.8
<0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Motor −8.8 −11.6* −15.9* −4.5 −7.3 −11.3*
<0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Fatigue −5.7 −3.8 −12.3* −4.9 −3.7 −8.3
<0.001 <0.001 <0.001 <0.001 <0.001 <0.001
GI/seizures/bladder  
control 
−3.7 −3.6 −3.4 −3.6 −1.3 −2.8
<0.001 <0.001 <0.001 <0.001 0.067 0.001
Single symptoms a
Dyspnea −5.1 −6.8 −9.4 −5.5 −3.1 −6.6
<0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Insomnia −1.3 −1.3 −2.9 −7.3 −0.46 −5.8
0.032 0.020 0.001 <0.001 0.498 <0.001
Appetite loss −3.8 −3.6 −3.4 −5.3 −5.2 −4.5
<0.001 <0.001 0.001 <0.001 <0.001 <0.001
Constipation −2.0 −0.07 −2.0 −2.5 −3.3 −1.8
0.003 0.905 0.039 0.001 <0.001 0.063
Visual disorder −4.9 −2.9 −6.9 −4.5 −14.6* −5.7
<0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Communication deficit −2.6 −.36 −3.3 −4.0 −16.4* −4.3
<0.001 0.535 <0.001 <0.001 <0.001 0.87
Hair loss −1.0 −.82 1.7 −2.8 0.11 −2.5
0.172 0.247 0.130 0.001 0.894 0.018
Itchy skin 0.33 −0.42 0.30 −0.48 0.63 −2.5
0.655 0.535 0.778 0.555 0.448 0.013
Clinical/sociodemographic variables
Age −0.12 −0.13 −0.05 −0.01 −0.05 0.06
<0.001 <0.001 0.139 0.861 0.064 0.076
Female sex (ref: male) −0.24 −4.62 −0.00 −2.1 −0.96 −0.36
0.689 <0.001 00.998 0.001 0.157 0.668
Surgery (ref: biopsy only) 2.26 1.34 −0.27 1.78 1.79 0.50
0.003 0.06 0.809 0.034 0.037 0.64
Gr IV glioblastoma  
(ref: Gr II/III, A/O/OA)
−0.15 3.2 −0.84 −1.64 −0.28 0.51
0.831 <0.001 0.425 0.037 0.731 0.61
WHO PS 2  
(ref: WHO PS 0–1)
−3.3 −7.8 −9.7 −1.27 −3.18 −5.4
<0.001 <0.001 <0.001 0.015 <0.001 <0.001
Gr, grade of the tumor; A, astrocytoma; O, oligondendroglioma; OA, oligoastrocytoma; aseverity of symptoms ranging from mild to severe; *clinically 
relevant difference (≥10 points).
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as both bodily pain and headache. Indeed, headache is a 
known presenting symptom in brain tumor patients.44 
Similar to what has been reported in previous studies, 
headache and pain were present in almost half of the pa-
tients (both 44%).45,46 Most patients who experienced pain 
also experienced headache (74%), and vice versa (73%). 
However, although the correlation between pain and head-
ache was the second highest found in our study (.57), it can 
still be interpreted as moderate, indicating that they do not 
measure the same concept. This is also true for fatigue and 
drowsiness, with a correlation of .59.
One unexpected finding is the clustering of nausea 
and vomiting, diarrhea, seizures, and bladder control. 
Clustering of GI symptoms was found in earlier studies; 
however, in our study the symptoms of appetite loss and 
constipation did not cluster with nausea and vomiting 
and diarrhea. An explanation for the clustering of these 
symptoms may be statistical, as each of these symptoms 
showed floor effects.41 These symptoms are the 4 least re-
ported, all experienced by less than 25% of the patients 
(Table 2), and clustering of these symptoms in the HCA 
may be the result of numerical similarities rather than clin-
ical similarities.
Although almost all symptom clusters showed a sta-
tistically significant association with the level of func-
tioning and the global health status/QoL, only the motor 
and fatigue clusters were independently associated—ie, 
adjusted for important clinical characteristics, with role 
functioning (both clusters), physical functioning, and so-
cial functioning (the motor cluster) at a level that can be 
considered clinically relevant. Post hoc analyses showed 
that patients who experience symptoms in more symptom 
clusters experience impaired functioning to a larger extent 
and on more functioning scales. Although not surprising, 
this study is the first to observe an association between 
symptom clusters and functioning in glioma patients. 
Similar results were found in other cancer populations: a 
pain/fatigue/cognitive cluster impacted physical, role, and 
social functioning in advanced cancer patients,10 and an 
emotional cluster was found to negatively influence role 
and social functioning in patients with lung, breast, colo-
rectal, and stomach cancer undergoing palliative chemo-
therapy.47 The results of our study suggest that a clinically 
relevant improvement in functioning could be achieved by 
relieving motor and fatigue symptoms in glioma patients. 
As the fatigue and motor clusters were also the most fre-
quently affected clusters, and since most patients expe-
rienced symptoms in both, reducing the burden of these 
symptoms may benefit the majority of glioma patients in 
terms of improved functioning. Also, fatigue and motor 
problems were found to be most central to other symp-
toms (Fig. 2, Supplementary Fig. 3), suggesting that allevi-
ating these symptoms most likely will positively influence 
the other symptoms as well. Fatigue and motor problems 
are, however, not easily treated. There is little evidence for 
pharmacological and non-pharmacological interventions 
for fatigue in glioma patients.48,49 The literature on inter-
ventions targeting motor problems is scarce, although 
mobility was improved in patients undergoing multidisci-
plinary treatment including physical exercise.50,51
One important limitation of this study is the selec-
tion bias toward a healthier population, as the patients 
included in our analyses were those deemed fit enough 
to participate in an RCT and who also completed HRQoL 
questionnaires. This could potentially limit the generaliza-
bility of the results. Another limitation is that only baseline 
data were used in the analyses, and we do not know if the 
clusters identified at pretreatment are stable during fol-
low-up. Moreover, only symptoms were included that were 
measured with the QLQ-C30 and the QLQ-BN20 question-
naires. Some relevant symptoms, such as mood disorders 
or cognitive complaints, were not covered, and therefore 
the use of instruments that specifically and extensively 
measure symptoms may be more useful. Furthermore, we 
included glioma patients with different tumor types in the 
analyses and, besides the subgroups glioblastoma/non-
glioblastoma, could not look further into different molec-
ular subtypes. One implication could be that the results of 
our study may not be generalizable to all glioma subtypes, 
as we saw for the GI/seizures/bladder control cluster, which 
was not found in non-glioblastoma patients. Another lim-
itation is that, in the regression analyses, the severity of 
the symptoms was not taken into account, as patients 
were classified as having “no symptoms” or “symptoms.” 
One could hypothesize that patients with more severe 
symptoms in the symptom clusters experience more im-
paired functioning than patients with mild symptoms only. 
Another limitation concerns the choices made regarding 
the definition of “symptom clusters” and the method used 
to identify them. First, different definitions of a symptom 
cluster exist, and there is no consensus on the minimum 
number of symptoms required to form a symptom cluster. 
We chose to define a symptom cluster as consisting of at 
least 2 symptoms. Of course, this choice impacted our re-
sults, as for example the fatigue cluster consists of only 
two symptoms. Further, the identified symptom clusters, 
for which we have combined 3 frequently used methods 
(ie, correlation analysis, partial correlation analysis, and 
HCA), might have been different when other methods 
were used—for example, factor analyses. Which is the best 
method remains a matter of debate.52
Even though the mentioned selection bias may hamper 
generalizability of the study results and is limited because 
of the overrepresentation of patients with a better health 
status, these results may have potential clinical impli-
cations. As most patients experience between 5 and 10 
symptoms simultaneously, many symptoms may remain 
unnoticed as only the most severe symptoms are likely 
to be discussed during a consultation, and subsequently 
treated. Awareness of patients experiencing multiple con-
current symptoms and of the existence of symptom clus-
ters and their association with functioning as measured 
with a self-report questionnaire might help clinicians to 
identify and treat patients with these symptoms in a more 
timely manner. Also, the awareness of the presence of 
these co-occurring symptoms could help clinicians to de-
velop interventions with the intention to treat or prevent 
problems that appear together. Multimodal rehabilitation 
programs, for example, can be effective in treating mul-
tiple symptoms53 and may subsequently improve func-
tioning. Furthermore, the identified symptom clusters 
may provide insight into the underlying mechanisms that 
caused these symptoms. It should be kept in mind, how-
ever, that the current study identified symptom clusters 
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before the initiation of antitumor treatment including ra-
diotherapy and/or chemotherapy. Further research should 
aim at investigating symptom clusters over time, to deter-
mine whether the identified symptom clusters are stable 
during the treatment and follow-up phases. Ideally, a pro-
spective study investigating symptom clusters at baseline 
and during follow-up phases would allow us to examine 
the impact of a specific treatment regimen and the sta-
bility of symptom clusters over time. Moreover, future 
studies could also examine the (added) predictive value 
of symptom clusters for survival. This would be helpful in 
initiating interventions at the time patients benefit most 
from these treatment strategies.
Supplementary Material
Supplementary data are available at Neuro-Oncology 
online.
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